On March 29, 2016 ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, reported the presentations related to the Company’s technology portfolio to be made at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) annual meeting being held April 16-20, 2016 in New Orleans, LA (Press release, ImmunoGen, MAR 29, 2016, View Source [SID:1234510110]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
ImmunoGen is a recognized leader in the ADC field and invests in new technologies to further extend the types of cancers potentially treatable with this therapeutic approach. Presentations at AACR (Free AACR Whitepaper) relate to:
Cancer-killing agent/linker innovations – ImmunoGen and partner ADCs in the clinic today all utilize one of the Company’s tubulin-acting maytansinoid agents attached to an antibody using an engineered ImmunoGen linker. The Company has developed a new class of cancer-killing agents – DNA-alkylating IGNs – and multiple purpose-driven linkers and will report new IGN/linker data (abstract #2959).
Site-specific attachment innovations – Preclinical studies suggest advantages to site-specific attachment of IGNs, and the Company will have several presentations about site-specific technology innovations (abstracts #2960, #2965, and #2967).
Partner program preclinical research – In addition to ImmunoGen’s product programs, nine healthcare companies have licensed rights to utilize Company technology to develop ADCs for specific targets. Two partners will report preclinical ADC data (abstracts #872, #1197, #1198, and #2974).
Additional information – including presentation schedule, titles and full abstracts – can be found at www.aacr.org